scispace - formally typeset
R

Ralitza Gueorguieva

Researcher at Yale University

Publications -  242
Citations -  15200

Ralitza Gueorguieva is an academic researcher from Yale University. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 53, co-authored 210 publications receiving 13013 citations. Previous affiliations of Ralitza Gueorguieva include Emory University & Veterans Health Administration.

Papers
More filters
Journal ArticleDOI

Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry.

TL;DR: Mixed-effects models use all available data, can properly account for correlation between repeated measurements on the same subject, have greater flexibility to model time effects, and can handle missing data more appropriately makes them the preferred choice for the analysis of repeated-measures data.
Journal ArticleDOI

The psychotomimetic effects of intravenous Delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis

TL;DR: It is indicated that Δ-9-THC produces a broad range of transient symptoms, behaviors, and cognitive deficits in healthy individuals that resemble some aspects of endogenous psychoses and warrant further study of whether brain cannabinoid receptor function contributes to the pathophysiology of psychotic disorders.
Journal ArticleDOI

Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression.

TL;DR: The study replicates the findings of decreased GABA concentrations in the occipital cortex of subjects with MDD and demonstrates that there is a change in the ratio of excitatory-inhibitory neurotransmitter levels in the cortex of depressed subjects that may be related to altered brain function.
Journal ArticleDOI

Association between physical exercise and mental health in 1·2 million individuals in the USA between 2011 and 2015: a cross-sectional study

TL;DR: In a large US sample, physical exercise was significantly and meaningfully associated with self-reported mental health burden in the past month, and differences as a function of exercise were large relative to other demographic variables such as education and income.
Journal ArticleDOI

Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

TL;DR: Delta-9-tetrahydrocannabinol is associated with transient exacerbation in core psychotic and cognitive deficits in schizophrenia, and this data do not provide a reason to explain why schizophrenia patients use or misuse cannabis.